Percutaneous catheter-based transluminal renal nerve ablation (RNA) by delivery of radiofrequency energy constitutes a novel therapeutic strategy for the treatment of resistant hypertension. The sympathetic nervous activation to the kidney and the sensory afferent signals to the central nervous system represent the targets of RNA. In this review we summarize current recommendations for appropriate patient selection for RNA and multimodal strategies in order to optimize pharmacological treatment for resistant hypertension. The safety and efficacy of the RNA based on published trials are also presented. Furthermore, a detailed description of the periprocedural management, the methodology of the RNA procedure and appropriate follow-up are provided. In conclusion, in order to improve the overall clinical outcome and achieve optimal management of resistant hypertensive patients before and after the RNA, experienced and certified centers are of major importance.
Keywords: Invasive procedure, renal denervation, resistant hypertension.
Hypertension in Peripheral Arterial Disease
Current Pharmaceutical Design Pure Polyphenols Applications for Cardiac Health and Disease
Current Pharmaceutical Design Overview of Hyperuricaemia and Gout
Current Pharmaceutical Design Natriuretic Peptides in Heart Failure and Post-Myocardial Infarction
Current Hypertension Reviews Should Cushing’s Syndrome be Considered as a Disease with High Cardiovascular Risk in Relevant Guidelines?
Current Vascular Pharmacology Emerging Vascular Risk Factors in Women: Any Differences from Men?
Current Medicinal Chemistry Therapeutic Approaches for the Management of Sleep Disorders in Geriatric Population
Current Medicinal Chemistry Atherogenesis in Renal Patients: A Model of Vascular Disease?
Current Vascular Pharmacology Recent Advances in Pulmonary Hypertension Therapy
Recent Patents on Cardiovascular Drug Discovery (Discontinued) ACE Inhibitors for the Treatment of Hypertension Drug Selection by Means of the SOJA Method
Reviews on Recent Clinical Trials Hypoxia-Inducible Factor-1 in Arterial Disease: A Putative Therapeutic Target
Current Vascular Pharmacology Essentials of Daflon 500 mg: From Early Valve Protection to Long-Term Benefits in the Management of Chronic Venous Disease
Current Pharmaceutical Design Dopamine β-Monooxygenase: Mechanism, Substrates and Inhibitors
Current Enzyme Inhibition Molecular Mechanisms of Renal Blood Flow Autoregulation
Current Vascular Pharmacology Cardiovascular Aspect of Beta-Thalassaemia
Cardiovascular & Hematological Agents in Medicinal Chemistry Is Hypertension an Inflammatory Process?
Current Pharmaceutical Design Pomegranate Consumption and Blood Pressure: A Review
Current Pharmaceutical Design Medicinal Chemistry and Pharmacology of A2B Adenosine Receptors
Current Topics in Medicinal Chemistry Early Urinary Markers for Diabetic and Other Kidney Diseases
Current Drug Targets Hypertension and Heart Failure with Preserved Ejection Fraction: Connecting the Dots
Current Vascular Pharmacology